Casdin Capital

Biopharmaceutical research and development company that's an affiliate of Clover Health

Celsius Therapeutics is a biotechnology company focused on developing innovative medicines to treat complex diseases, including autoimmunity and cancer. Founded in 2017 and based in Cambridge, Massachusetts, the company leverages advanced techniques such as single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. By systematically applying single-cell sequencing and analyzing extensive datasets with sophisticated algorithms, Celsius Therapeutics aims to discover critical biomarkers and precision therapies that enhance patient care and enable clinicians to identify genes that play a causal role in various conditions.

Developer of mRNA-based pathway activity profiling technology designed to revolutionize precision medicine by obtaining more insight into the mechanisms of disease. The company offers to utilize its extensive database with pathway activity profiles to support diagnostics and drug development, providing researchers with qPCR tests for decentralized use via a service testing facility in The Netherlands.

Deepcell, Inc. is a company based in Mountain View, California, focused on advancing diagnostic technologies through a non-invasive approach. Founded in 2015, it has developed a microfluidic imaging platform that leverages artificial intelligence to classify cells by their visual features. This technology allows for the isolation of viable cells based on their morphological characteristics, facilitating detailed genetic health assessments from standard blood samples. By enabling insights at the single-cell level, Deepcell aims to improve the diagnosis and treatment of various diseases, offering researchers a valuable alternative to invasive diagnostic methods.

Operator of a biotechnology company intended to provide novel small molecule medicines targeting g-protein-coupled receptors. The company provides industrial-scale drug discovery using novel screening technologies and structure-based drug design, enabling medical researchers to easily find patients' treatments for a wide range of diseases.

Fluidigm Corporation develops and markets innovative technologies and tools for life sciences research globally. The company specializes in integrated fluidic circuits that control fluids at the nanoscale, enabling a range of applications in biological research. Its product offerings include analytical systems such as the Helios CyTOF system, the Hyperion imaging system, and the Biomark HD system, along with various assays and reagents designed for immuno-oncology and genetic analysis. Fluidigm also provides preparatory instruments and single-cell microfluidics, such as the C1 and Polaris systems. The company serves a diverse clientele, including academic institutions, clinical research laboratories, biopharmaceutical, biotechnology, and agricultural biotechnology companies, focusing on non-diagnostic and non-clinical applications. Established in 1999 as Mycometrix Corporation, it adopted the name Fluidigm Corporation in 2001 and is headquartered in South San Francisco, California.

Verana Health, Inc. is a software company dedicated to improving the connection between healthcare providers and mobile diagnostics. Based in San Francisco, the company provides a range of tools designed to facilitate real-time access to diagnostic data for both patients and physicians. Its flagship product, SightBook, is a mobile application that allows users to assess their vision and share results with their healthcare providers instantly, while also enabling physicians to manage appointments and treatments effectively. In addition to SightBook, Verana Health offers a cloud-based portal, a smartphone application for vision assessments, mobile imaging devices, and analytics tools that support the monitoring of patient data. By partnering with leading medical associations, Verana Health transforms clinical data into actionable insights, helping to accelerate medical research and improve patient care. The company was previously known as Digisight Technologies, Inc. before rebranding in July 2018 and has been operational since its incorporation in 2008.

Oxford NanoImaging Limited specializes in the development and manufacture of advanced microscopy tools for life sciences research. The company's flagship product, the Nanoimager, is a single-molecule fluorescence microscope designed to detect biomolecules, including disease-related protein markers and pathogens, at single copy numbers. This innovative microscope features capabilities such as 3D imaging and dual-color super-resolution, enhancing researchers' ability to study complex biological processes. In addition to the Nanoimager, Oxford NanoImaging offers various microscopy technologies, including Förster Resonance Energy Transfer microscopy, direct stochastic optical reconstruction microscopy, and photoactivated localization microscopy. Founded in 2016 and headquartered in London, with an additional office in Menlo Park, California, the company aims to make life science tools and knowledge accessible to a wider audience.

Depixus SAS is a biotechnology company based in Paris, France, focused on the development of advanced technology for extracting genetic and epigenetic information from single molecules of DNA and RNA. Its main product, SIMDEQ™ (SIngle-molecule Magnetic DEtection and Quantification), enables fast, accurate, and cost-effective analysis of genomes and epigenetic modifications. Initially developed at École Normale Supérieure by prominent researchers, SIMDEQ™ allows for the identification, counting, full sequencing, and epityping of millions of individual DNA molecules with high precision. The technology has broad applications in the life sciences and medical fields, facilitating real-time analysis of biomolecular interactions and supporting researchers in uncovering new biological pathways, understanding disease mechanisms, and advancing precision medicine. With substantial validation completed, Depixus is moving towards platform optimization and commercialization to enhance its offerings in these critical areas.

Exai Bio is a next-generation liquid biopsy company that specializes in the early and accurate diagnosis of cancer. The company has developed a proprietary platform that analyzes cell-free RNA profiles, utilizing advanced artificial intelligence and machine learning algorithms. This technology focuses on orphan non-coding RNA and small RNA sequences that are prevalent in tumors but absent in normal tissue. By delivering clinical insights into cancer biology, Exai Bio's platform aids healthcare professionals in identifying cancer at its earliest stages and informs personalized treatment options for patients.

Nplex Biosciences is a biotechnology company based in the United States that specializes in proteomic technology. The company has developed a platform that utilizes DNA nanotechnology to understand, detect, and treat diseases. Nplex offers a range of instruments and automation tools for measuring multiple proteins from blood samples, providing cost-effective solutions for protein data analysis. Its technology integrates seamlessly with industry-standard cytometers, enabling high-throughput analysis and the development of custom protein panels. Nplex aims to enhance existing instruments and workflows while facilitating automation in proteomic research and applications.

Lunit Inc. is a South Korean company that specializes in developing advanced algorithms for medical image analysis and general object detection using machine learning technology. The firm focuses on areas such as digital chest X-ray, digital mammography, digital pathology, and fundus photography. By leveraging cutting-edge deep learning techniques, Lunit aims to assist physicians in making accurate and efficient clinical decisions. The company has demonstrated its expertise in image recognition, having ranked among the top five in the ImageNet Challenge, a prominent competition in the field. Lunit's technology is notable for its ability to utilize weakly labeled data, enhancing its pattern recognition capabilities. Supported by significant venture capital investments, Lunit is actively engaged in large-scale research collaborations with major university hospitals in South Korea, reflecting its strong reception within the medical community.

Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

Chroma Medicine is a genomic medicine company focused on epigenetic editing to transform the treatment of genetically driven diseases. By leveraging epigenetics, which regulates gene expression naturally, Chroma Medicine aims to develop innovative therapies that provide precise control over gene activity. The company utilizes programmable epigenetic editors that combine DNA binding domains with epigenetic effector domains, allowing for targeted manipulation of genes and chromatin structure. This approach promises to create a new class of therapeutics that offers unparalleled control over gene expression, potentially leading to more effective treatments for a range of genetic disorders.

Developer of an artificial intelligence-based EEG analysis and diagnosis platform designed to improve human health by providing rapid, targeted interventions through advanced brain analytics. The company's platform can capture real-time brain activity and assist professionals with the study of neurological and psychiatric diseases, enabling healthcare professionals to quantify treatment plans and identify the optimal patient population.

Qloudlab specializes in innovative healthcare solutions, particularly through its development of Sceptre, the world's first touchscreen-based biosensor. This modular platform facilitates a wide range of diagnostic tests, including blood, urine, saliva, and skin analyses, all within a single mobile system. By integrating smartphone technology with healthcare and cloud computing, Qloudlab aims to streamline diagnostics at the Point-of-Care, making testing more accessible and efficient. The company's technology is designed to be cost-effective, enhancing the user experience for both patients and healthcare professionals. Through its advancements, Qloudlab is positioned to transform the diagnostics landscape, ensuring that essential health information is readily available and easily obtainable.

Thyme Care is a Nashville TN-based provider of oncology care management solutions.

Xcell Biosciences, Inc. is a San Francisco-based life science company founded in 2012 that focuses on developing innovative technologies for cancer cell analysis and immunotherapy. The company specializes in a proprietary bench-top system that allows for the capture, growth, and analysis of primary cells directly from patient blood samples. This technology is designed to enhance the control of cell phenotype and function, thereby optimizing the efficacy and persistence of immune cell therapies. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences aims to empower researchers with advanced tools for cell maintenance and expansion, ultimately facilitating predictive therapy development and improving clinical outcomes.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

NanoCellect Biomedical, Inc. develops innovative flow cytometry and cell sorting technology aimed at enhancing the capabilities of life science researchers in cellular analysis, molecular diagnostics, and personalized medicine. Founded in 2009 and based in San Diego, California, the company offers the WOLF Cell Sorter, which utilizes a closed fluid-path microfluidic cartridge to facilitate cell sorting while minimizing biohazard risks and shear stress commonly associated with traditional methods. By making flow cytometry more affordable and accessible, NanoCellect aims to support biomedical researchers in analyzing and isolating cells efficiently, thereby promoting significant advancements in drug discovery and diagnostics. The company's technology is designed to provide rapid, objective, and quantitative data on individual cells, empowering scientists to conduct essential research with greater ease and precision.

Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.

Hexagon Bio, Inc. is a biotechnology company based in Menlo Park, California, that specializes in mining genomic data from fungal genomes to develop targeted small molecule therapeutics for diseases with unmet medical needs. Founded in 2016, the company leverages a proprietary platform that integrates data science, synthetic biology, and automation to discover and engineer novel drugs. By focusing on evolutionarily refined molecules and their corresponding protein targets, Hexagon Bio aims to identify and develop new medicines from the global metagenome, ultimately striving to enhance patient outcomes through innovative therapeutic solutions.

23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.

Nautilus Biotechnology is a development-stage life sciences company focused on advancing proteomics, the study of proteins and their functions, to enhance therapeutic development and medical diagnostics. The company has created a platform technology that aims to quantify and unravel the complexities of the human proteome. Its flagship product, the Proteomic Analysis System, is a prototype single-molecule instrument designed to facilitate these efforts. The team at Nautilus comprises experts from various disciplines, including protein chemistry, molecular biology, and data science, enabling a multifaceted approach to overcoming challenges in the field. By harnessing this diverse expertise, Nautilus aims to revolutionize drug development and improve healthcare management through personalized and predictive medicine.

LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.

Our fundamental technology, Printed Droplet Microfluidics (PDM), is a flexible and reconfigurable fluid handling system to perform picoliter-scale manipulations. By leveraging fluorescence-activated microfluidic droplet sorting and a specialized substrate, PDM enables the flexible and deterministic handling of single cells and fluid aliquots at extremely high throughputs. ​

Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.

Apton Biosystems, Inc., founded in 2012 and based in Pleasanton, California, operates within the biotechnology sector, focusing on innovative solutions for genetic analysis. The company has developed a high-throughput and low-cost sequencing platform that enhances the availability of genetic testing, facilitating biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems reimagines optical systems for sequencing and single-molecule protein detection, utilizing super-resolution technology to evaluate closely spaced molecules. This approach enables the healthcare sector to create well-defined nanostructures, addressing spatial challenges and advancing high-density sequencing and protein detection capabilities. Through these advancements, Apton Biosystems contributes to the fields of preventive health and precision medicine.

C2i Genomics, Inc. specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-surgery cancer patients. The company offers an ultra-sensitive liquid biopsy assay that analyzes subtle changes in tumor DNA, enabling physicians to monitor treatment responses and detect disease recurrence or treatment failure significantly earlier than traditional methods. C2i Genomics employs a bio-platform approach applicable across various cancer types, facilitating the guidance of multiple treatment modalities, including surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, the company provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. Established in 2019, C2i Genomics is headquartered in New York, New York, with a research and development center located in Haifa, Israel.

Komodo Health Inc. is a healthcare technology company that provides a platform for healthcare data aimed at enhancing decision-making and transparency in the industry. Founded in 2014 and headquartered in New York, with an additional office in San Francisco, the company offers various software applications, including Healthcare Map, which tracks patient outcomes across the healthcare system. Its solutions, such as Aperture, Pulse, and Serenity, deliver valuable insights by analyzing extensive data from patients, practitioners, and health systems. These applications enable health and life sciences enterprises to identify insights, address gaps in care, and reduce the burden of disease, thereby setting a new standard for real-world data and analytics in healthcare.

Developer of a multi-omic platform designed to accelerate advancements in life science and medicine. The company's platform leverages DNA nanotechnology to develop solutions for biomedical applications by providing comprehensive data, thereby enabling doctors and patients to get an accurate and complete view of an individual's biochemistry with a single test.

Imagen is a healthcare company whose mission is to save patient lives by making accurate medical image interpretation universally available and affordable. Currently, over two-thirds of the world’s population doesn’t have access to basic radiology services. Through our technology and close collaboration with world-leading clinicians, we believe that we can do something about it. We take an interdisciplinary approach: we are a team of experts in machine learning, healthcare, software engineering, and regulatory affairs who research and develop assistive software for clinicians. Our FDA-cleared software analyzes the content of medical images and produces diagnoses, improving the diagnostic accuracy of clinicians by highlighting detected pathology. We are advised by some of the world’s leading scientists and medical researchers, including Turing Award winner Yann LeCun. We have raised over $60M from leading investors including GV, DFJ, and Zach Weinberg. Imagen is based in New York and actively hiring. Are you excited about joining our mission? Reach out directly to us at recruitingteam@imagen.ai

Paige builds software to advance the diagnosis, treatment, and biomarker discovery for cancer. The Memorial Sloan Kettering spin-out aims to help pathologists and clinicians make faster, more informed diagnostic and treatment decisions and to bring new digital biomarkers to their practice. Paige’s proprietary Machine Learning solutions provide insights from decades of data from the world’s experts in cancer care and were recently published in Nature Medicine. The company’s first product for prostate cancer detection received Breakthrough Designation from the FDA as a novel therapy that stands to improve diagnostic accuracy while reducing costs to health systems.

Paige builds software to advance the diagnosis, treatment, and biomarker discovery for cancer. The Memorial Sloan Kettering spin-out aims to help pathologists and clinicians make faster, more informed diagnostic and treatment decisions and to bring new digital biomarkers to their practice. Paige’s proprietary Machine Learning solutions provide insights from decades of data from the world’s experts in cancer care and were recently published in Nature Medicine. The company’s first product for prostate cancer detection received Breakthrough Designation from the FDA as a novel therapy that stands to improve diagnostic accuracy while reducing costs to health systems.

Octave Bioscience is an early-stage molecular diagnostics company based in Menlo Park, California, that specializes in neurodegenerative diseases, particularly multiple sclerosis. Co-founded in 2013 by Melinda Thomas and William Hagstrom, the company has developed a clinical platform that generates, analyzes, and integrates data to transform the care of neurodegenerative conditions. This platform adopts a multi-dimensional approach aimed at reducing overall healthcare costs through the optimization of medication use and healthcare services. Additionally, Octave's technology supports the pharmaceutical industry by enhancing the drug discovery process, clinical trials, and post-marketing activities through real-world evidence.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.

Oxford Nanopore Technologies Limited specializes in the development and commercialization of nanopore-based electronic systems for the analysis of single molecules, particularly in the fields of DNA and RNA sequencing. The company offers a range of products, including the portable MinION device for molecular analysis, the benchtop PromethION for large-scale sequencing projects, and the GridION system suitable for various molecular sensing applications. Their technology supports diverse scientific research areas such as genomics, cancer studies, microbiology, and environmental research, with applications extending to healthcare, agriculture, and food safety. The Flongle device caters to on-demand sequencing needs, while the MinIT accessory enhances the functionality of their sequencing devices. Oxford Nanopore’s innovative technology emphasizes accessibility and ease of use, with rapid library preparation and automated processes. Founded in 2005 and headquartered in Oxford, United Kingdom, the company operates additional offices worldwide, enabling its products to be utilized in over 80 countries.

A2 Biotherapeutics is an early-stage biotechnology company located in Southern California that develops novel medicines for serious illnesses. We utilize an advanced targeting technology platform to increase the effectiveness of the body’s natural immune defenses.

Oxford NanoImaging Limited specializes in the development and manufacture of advanced microscopy tools for life sciences research. The company's flagship product, the Nanoimager, is a single-molecule fluorescence microscope designed to detect biomolecules, including disease-related protein markers and pathogens, at single copy numbers. This innovative microscope features capabilities such as 3D imaging and dual-color super-resolution, enhancing researchers' ability to study complex biological processes. In addition to the Nanoimager, Oxford NanoImaging offers various microscopy technologies, including Förster Resonance Energy Transfer microscopy, direct stochastic optical reconstruction microscopy, and photoactivated localization microscopy. Founded in 2016 and headquartered in London, with an additional office in Menlo Park, California, the company aims to make life science tools and knowledge accessible to a wider audience.

Lyra Health, Inc. is a Burlingame, California-based company that operates a digital platform connecting employers with mental health care providers. Founded in 2015, Lyra Health aims to improve access to effective mental health care for employees by utilizing innovative matching technology. The platform enables members to find personalized care by connecting them to a curated network of therapists and coaches, facilitating live video therapy and offering digital self-care tools. Lyra Health assesses treatment outcomes using clinical measures, such as the PHQ-9 and GAD-7, to monitor symptom improvement for conditions like anxiety and depression. This approach has resulted in significantly higher engagement and better outcomes compared to traditional mental health plans. Through its services, Lyra Health helps employees navigate the mental health system, schedule appointments, and maintain support throughout their treatment journey.

GeneMatters is a provider of genetic counseling services aimed at enhancing patient access to genetic insights through a scalable telehealth platform. Established in 2016 and based in Minneapolis, Minnesota, the company operates an online genetic counseling network that offers pre-test and full-service genetic counseling, as well as caregiving services. By collaborating with hospitals, health networks, clinics, academic research centers, and genetic testing labs, GeneMatters facilitates a better understanding of genetic family history, allowing users to make informed decisions based on their genetic tests. The company’s services are designed to integrate seamlessly with existing patient workflows, ensuring flexible staffing and clinical expertise are readily available.

Goldfinch Bio, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing precision therapies for kidney diseases. The company focuses on researching and commercializing treatments for conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Notable programs include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio is also developing the Kidney Genome Atlas, a genomic registry aimed at identifying new disease targets and biomarkers, and utilizes a biology platform that leverages stem cell science to create human organoid models for target validation. Founded in 2016 and based in Cambridge, Massachusetts, Goldfinch Bio has established a strategic collaboration with Gilead Sciences to enhance its capabilities in kidney disease therapy development.

C2i Genomics, Inc. specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-surgery cancer patients. The company offers an ultra-sensitive liquid biopsy assay that analyzes subtle changes in tumor DNA, enabling physicians to monitor treatment responses and detect disease recurrence or treatment failure significantly earlier than traditional methods. C2i Genomics employs a bio-platform approach applicable across various cancer types, facilitating the guidance of multiple treatment modalities, including surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, the company provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. Established in 2019, C2i Genomics is headquartered in New York, New York, with a research and development center located in Haifa, Israel.

Biopharmaceutical research and development company that's an affiliate of Clover Health

Lyra Health, Inc. is a Burlingame, California-based company that operates a digital platform connecting employers with mental health care providers. Founded in 2015, Lyra Health aims to improve access to effective mental health care for employees by utilizing innovative matching technology. The platform enables members to find personalized care by connecting them to a curated network of therapists and coaches, facilitating live video therapy and offering digital self-care tools. Lyra Health assesses treatment outcomes using clinical measures, such as the PHQ-9 and GAD-7, to monitor symptom improvement for conditions like anxiety and depression. This approach has resulted in significantly higher engagement and better outcomes compared to traditional mental health plans. Through its services, Lyra Health helps employees navigate the mental health system, schedule appointments, and maintain support throughout their treatment journey.

Verana Health, Inc. is a software company dedicated to improving the connection between healthcare providers and mobile diagnostics. Based in San Francisco, the company provides a range of tools designed to facilitate real-time access to diagnostic data for both patients and physicians. Its flagship product, SightBook, is a mobile application that allows users to assess their vision and share results with their healthcare providers instantly, while also enabling physicians to manage appointments and treatments effectively. In addition to SightBook, Verana Health offers a cloud-based portal, a smartphone application for vision assessments, mobile imaging devices, and analytics tools that support the monitoring of patient data. By partnering with leading medical associations, Verana Health transforms clinical data into actionable insights, helping to accelerate medical research and improve patient care. The company was previously known as Digisight Technologies, Inc. before rebranding in July 2018 and has been operational since its incorporation in 2008.

At WGA our mission is to bring genomic products to policyholders and employees around the world through trusted life insurance and employee benefit brokers. We believe the genomic industry and its discoveries will enhance healthy life and longevity. WGA stands at the crossroads of these two industries. We use our collective knowledge to guide our clients in their successful adaptation of this new technology.

Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics. The company's focus is to identify individuals and populations around the world who are extreme outliers for traits of medical relevance and to use innovative sequencing and analytic approaches to identify genes and pathways linked to these traits. It was founded in 2018 and headquartered in Seattle, Washington.

Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.

Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.

908 Devices Inc. is a Boston-based company that develops and sells advanced measurement devices for chemical and biochemical analysis, utilizing mass spectrometry technology. The company's product lineup includes handheld and desktop devices designed for immediate, on-site analysis across various fields such as life sciences, bioprocessing, industrial biotechnology, and forensics. Notable products include the MX908, a portable mass spectrometry device for rapid analysis of unknown substances, the Rebel desktop analyzer for real-time monitoring of bioprocess environments, and the ZipChip, a high-resolution separation platform that enhances mass spectrometry sample analysis. Established in 2012, 908 Devices aims to make mass spectrometry accessible beyond traditional laboratories, providing reliable tools for professionals needing quick and actionable insights. The company operates mainly in the United States while also serving markets in Europe, Asia, and beyond.

Singular Bio, Inc. is a San Francisco-based company founded in 2012 that specializes in diagnostic testing for personalized medicine. The company has developed a cutting-edge technology for single molecule analysis of DNA, which offers exceptional sensitivity in detecting various common health conditions. Singular Bio's proprietary detection system aims to address the needs of high-volume healthcare testing, combining the accuracy of genetic analysis with the affordability and rapid results typically associated with screening tests. By leveraging advanced optics alongside custom molecular biology and chemistry, Singular Bio seeks to enhance healthcare accessibility and enable early detection of medical conditions for a broader population. As of mid-2019, Singular Bio operates as a subsidiary of Invitae Corporation.

Prominex, Inc. is a San Diego-based company that specializes in the development and manufacturing of molecular diagnostic assays for Point-of-Care (POC) infectious disease testing. Established in 2016, Prominex has created the Validex System, which streamlines the diagnostic process by eliminating the need for thermal cycling and various complex components typically required in molecular diagnostics. This innovative system allows for the analysis of crude clinical samples and produces lab-quality results using proprietary molecular chemistry and detection technologies. Prominex's diagnostic tools are designed to address a range of infectious diseases, including sexually transmitted infections, influenza, and bloodstream infections, thereby enhancing the accessibility and efficiency of patient diagnostics.

Imagen is a healthcare company whose mission is to save patient lives by making accurate medical image interpretation universally available and affordable. Currently, over two-thirds of the world’s population doesn’t have access to basic radiology services. Through our technology and close collaboration with world-leading clinicians, we believe that we can do something about it. We take an interdisciplinary approach: we are a team of experts in machine learning, healthcare, software engineering, and regulatory affairs who research and develop assistive software for clinicians. Our FDA-cleared software analyzes the content of medical images and produces diagnoses, improving the diagnostic accuracy of clinicians by highlighting detected pathology. We are advised by some of the world’s leading scientists and medical researchers, including Turing Award winner Yann LeCun. We have raised over $60M from leading investors including GV, DFJ, and Zach Weinberg. Imagen is based in New York and actively hiring. Are you excited about joining our mission? Reach out directly to us at recruitingteam@imagen.ai

Oxford NanoImaging Limited specializes in the development and manufacture of advanced microscopy tools for life sciences research. The company's flagship product, the Nanoimager, is a single-molecule fluorescence microscope designed to detect biomolecules, including disease-related protein markers and pathogens, at single copy numbers. This innovative microscope features capabilities such as 3D imaging and dual-color super-resolution, enhancing researchers' ability to study complex biological processes. In addition to the Nanoimager, Oxford NanoImaging offers various microscopy technologies, including Förster Resonance Energy Transfer microscopy, direct stochastic optical reconstruction microscopy, and photoactivated localization microscopy. Founded in 2016 and headquartered in London, with an additional office in Menlo Park, California, the company aims to make life science tools and knowledge accessible to a wider audience.

Celsius Therapeutics is a biotechnology company focused on developing innovative medicines to treat complex diseases, including autoimmunity and cancer. Founded in 2017 and based in Cambridge, Massachusetts, the company leverages advanced techniques such as single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. By systematically applying single-cell sequencing and analyzing extensive datasets with sophisticated algorithms, Celsius Therapeutics aims to discover critical biomarkers and precision therapies that enhance patient care and enable clinicians to identify genes that play a causal role in various conditions.

Lyra Health, Inc. is a Burlingame, California-based company that operates a digital platform connecting employers with mental health care providers. Founded in 2015, Lyra Health aims to improve access to effective mental health care for employees by utilizing innovative matching technology. The platform enables members to find personalized care by connecting them to a curated network of therapists and coaches, facilitating live video therapy and offering digital self-care tools. Lyra Health assesses treatment outcomes using clinical measures, such as the PHQ-9 and GAD-7, to monitor symptom improvement for conditions like anxiety and depression. This approach has resulted in significantly higher engagement and better outcomes compared to traditional mental health plans. Through its services, Lyra Health helps employees navigate the mental health system, schedule appointments, and maintain support throughout their treatment journey.

GenapSys, Inc. develops innovative DNA sequencing technologies for applied genomic testing and medical sequencing. The company's primary product, the GenapSys Sequencer, utilizes electrical-based detection for single nucleotide incorporations, facilitating sequencing in various laboratory settings and automating clonal amplification. GenapSys offers solutions for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. Additionally, the company seeks to collaborate with local health agencies and researchers to enhance access to sequencing insights, particularly for controlling and mitigating outbreaks. The compact and portable nature of the sequencer allows it to operate from standard power sources, making it suitable for deployment in hospitals, airports, and public transportation hubs to provide rapid results for virus samples. Founded in 2010, GenapSys is headquartered in Redwood City, California.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Helix is a prominent population genomics company that operates at the intersection of clinical care, research, and data analytics. The company provides an end-to-end platform designed to facilitate genomic research and the incorporation of genomic data into healthcare practices. Helix operates one of the largest CLIA/CAP-certified next-generation sequencing laboratories and utilizes its proprietary Exome+™ assay to support various aspects of population genomics. These include recruitment and engagement, clinically actionable disease screening, and the return of results. Additionally, Helix engages in large-scale genetic analysis and viral surveillance, delivering actionable genetic insights that aid health systems, life sciences companies, payers, and government entities in enhancing patient care and informing public health decisions.

23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.

908 Devices Inc. is a Boston-based company that develops and sells advanced measurement devices for chemical and biochemical analysis, utilizing mass spectrometry technology. The company's product lineup includes handheld and desktop devices designed for immediate, on-site analysis across various fields such as life sciences, bioprocessing, industrial biotechnology, and forensics. Notable products include the MX908, a portable mass spectrometry device for rapid analysis of unknown substances, the Rebel desktop analyzer for real-time monitoring of bioprocess environments, and the ZipChip, a high-resolution separation platform that enhances mass spectrometry sample analysis. Established in 2012, 908 Devices aims to make mass spectrometry accessible beyond traditional laboratories, providing reliable tools for professionals needing quick and actionable insights. The company operates mainly in the United States while also serving markets in Europe, Asia, and beyond.

Flatiron Health, Inc. is a healthcare technology company that specializes in oncology, focusing on enhancing cancer research and patient care. The company has developed a data platform that integrates and organizes clinical and financial information from electronic medical records and billing systems. This platform, known as OncologyCloud, provides valuable analytics for cancer care providers and life sciences organizations, enabling them to track treatment patterns, monitor adherence to guidelines, and identify suitable candidates for clinical trials in real-time. Flatiron Health also offers additional tools such as OncoCloud for community oncology practices, Flatiron Assist for clinical decision support, and OncoEMR to assist providers in meeting oncology care model requirements. The company collaborates with over 280 community cancer practices, several major academic research centers, and prominent oncology companies. Founded in 2012 and based in New York, Flatiron Health operates as a subsidiary of Roche Holding AG.

23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.

Omniox is a biopharmaceutical company focused on developing innovative treatments for hypoxic diseases, which occur when tissues receive insufficient oxygen. This condition is linked to serious health issues, including various cancers and cardiovascular diseases. The company utilizes a proprietary protein-based platform technology known as H-NOX, which is designed to deliver oxygen and nitric oxide directly to hypoxic tissues. By specifically targeting these areas, Omniox aims to restore normal tissue function, potentially improving patient outcomes and offering new therapeutic options. Through its work, Omniox seeks to advance oxygen-based therapies that address the challenges posed by diseases associated with low oxygen levels.

Fabric Genomics is making genomics-driven precision medicine a reality. We provide clinical decision support software that enables clinical labs, hospital systems and country-sequencing programs to gain actionable genomic insights, resulting in faster and more accurate diagnoses and reduced turnaround time. Fabric’s end-to-end genomic analysis platform incorporates proven AI algorithms, and has applications in both hereditary disease and oncology. Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bioinformatics, large-scale genomics and clinical diagnostics.

Invitae is a genetic information company focused on integrating genetic testing into routine medical practice to enhance healthcare quality worldwide. It specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates a wide array of genetic tests into one platform, ensuring faster turnaround times and lower costs compared to traditional single-gene tests. Invitae's test offerings cover various hereditary conditions, including cancers, neurological disorders, cardiovascular diseases, pediatric and metabolic disorders. The company aims to make genetic testing more affordable and accessible, develop a secure infrastructure for genome management, and foster a global community for sharing genetic information to advance scientific research and medical practices. By lowering the barriers to obtaining diagnostic genetic information, Invitae seeks to improve healthcare outcomes for millions of individuals.

Ignyta is a scientifically-driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goal is to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide. Ignyta was incorporated in 2011 and operates in San Diego, California.

Foundation Medicine, Inc. specializes in providing molecular information products aimed at enhancing cancer treatment through genomic insights. The company utilizes proprietary methods and algorithms to analyze cancer specimens, helping physicians tailor treatments based on the unique genetic profile of each patient's tumor. Its product offerings include FoundationOne for solid tumors, FoundationOne Heme for hematologic malignancies, and various diagnostic assays such as FoundationFocus CDxBRCA for ovarian cancer. Additionally, Foundation Medicine develops a knowledgebase called FoundationCORE to disseminate scientific advancements within the oncology community. The company collaborates with major pharmaceutical firms and research organizations to advance precision medicine and develop companion diagnostics. Founded in 2009 and headquartered in Cambridge, Massachusetts, Foundation Medicine operates as a subsidiary of Roche Holdings, Inc. It aims to transform cancer care by enabling personalized treatment strategies informed by detailed genomic profiling.